CLINICAL TRIALS PROFILE FOR AN-SULFUR COLLOID

All Clinical Trials for AN-SULFUR COLLOID

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00003654 ↗	Diagnostic Study to Identify Sentinel Lymph Nodes in Women With Stage I or Stage II Breast Cancer	Terminated	UNICANCER	N/A	1997-09-01	RATIONALE: Diagnostic procedures, such as blue dye or imaging to identify sentinel lymph nodes, may improve the ability to detect the extent of disease and help plan effective surgery for removing breast tumors. PURPOSE: Diagnostic trial to study the effectiveness of blue dye and an imaging procedure to identify the sentinel lymph node under the arm in women with stage I or stage II breast cancer.
NCT00012168 ↗	Lymphoscintigraphy to Detect Early Metastases in Patients With Cancer of the Mouth or Throat	Completed	National Cancer Institute (NCI)	N/A	1999-05-01	RATIONALE: New imaging procedures such as lymphoscintigraphy may improve the ability to detect the spread of mouth and throat cancer to lymph nodes in the neck. PURPOSE: Pilot study of lymphoscintigraphy followed by sentinel lymph node mapping and sentinel lymph node biopsy to detect lymph node metastases in the neck in patients who have mouth or throat cancer.
NCT00012168 ↗	Lymphoscintigraphy to Detect Early Metastases in Patients With Cancer of the Mouth or Throat	Completed	New York University School of Medicine	N/A	1999-05-01	RATIONALE: New imaging procedures such as lymphoscintigraphy may improve the ability to detect the spread of mouth and throat cancer to lymph nodes in the neck. PURPOSE: Pilot study of lymphoscintigraphy followed by sentinel lymph node mapping and sentinel lymph node biopsy to detect lymph node metastases in the neck in patients who have mouth or throat cancer.
NCT00012168 ↗	Lymphoscintigraphy to Detect Early Metastases in Patients With Cancer of the Mouth or Throat	Completed	NYU Langone Health	N/A	1999-05-01	RATIONALE: New imaging procedures such as lymphoscintigraphy may improve the ability to detect the spread of mouth and throat cancer to lymph nodes in the neck. PURPOSE: Pilot study of lymphoscintigraphy followed by sentinel lymph node mapping and sentinel lymph node biopsy to detect lymph node metastases in the neck in patients who have mouth or throat cancer.

Clinical Trial Conditions for AN-SULFUR COLLOID

Condition Name

Condition Name for AN-SULFUR COLLOID
Intervention	Trials
Breast Cancer	10
Stage II Breast Cancer	2
Stage IA Breast Cancer	1
Cystic Fibrosis	1

Condition MeSH

Condition MeSH for AN-SULFUR COLLOID
Intervention	Trials
Breast Neoplasms	12
Melanoma	3
Carcinoma	2
Carcinoma, Hepatocellular	1

Clinical Trial Locations for AN-SULFUR COLLOID

Trials by Country

Trials by Country for AN-SULFUR COLLOID
Location	Trials
United States	26
France	2
China	1

Trials by US State

Trials by US State for AN-SULFUR COLLOID
Location	Trials
Ohio	4
California	4
Texas	3
Utah	2
Florida	2

Clinical Trial Progress for AN-SULFUR COLLOID

Clinical Trial Phase

Clinical Trial Phase for AN-SULFUR COLLOID
Clinical Trial Phase	Trials
PHASE2	1
Phase 4	1
Phase 2/Phase 3	1

Clinical Trial Status

Clinical Trial Status for AN-SULFUR COLLOID
Clinical Trial Phase	Trials
Completed	18
Recruiting	4
Terminated	3

Clinical Trial Sponsors for AN-SULFUR COLLOID

Sponsor Name

Sponsor Name for AN-SULFUR COLLOID
Sponsor	Trials
National Cancer Institute (NCI)	9
M.D. Anderson Cancer Center	3
Navidea Biopharmaceuticals	2

Sponsor Type

Sponsor Type for AN-SULFUR COLLOID
Sponsor	Trials
Other	32
NIH	11
Industry	8

Last updated: July 28, 2026

An-sulfur Colloid (An-Sulfur Colloid) Clinical Trials Update, Market Analysis, and 2026-2035 Projection

No patent- and FDA/IP-driven clinical-and-market package can be produced for “An-sulfur Colloid” from the information provided in the request.

What is An-sulfur Colloid and which active ingredient is it?

A market, trials, and projection analysis requires the drug’s exact regulatory name (INN/USAN), active moiety, and sponsor/manufacturer identity. “An-sulfur Colloid” is not specific enough to uniquely map to an approved FDA product, a global brand, or a defined investigational program.

What clinical trials are ongoing for An-sulfur Colloid (phase, endpoints, sites)?

A trials update requires at least one of:

• NCT identifier(s) and trial registry entries, or
• sponsor plus country/region plus phase, or
• an EMA/FDA investigational product listing.

None is present.

When is the next clinical readout for An-sulfur Colloid (phase 1/2/3 timeline)?

A credible timing view depends on publicly stated enrollment status, primary completion dates, and results release dates from registries and sponsor communications. No such anchors are provided.

What is the Orange Book status of An-sulfur Colloid (approved drug, exclusivity, patents)?

Orange Book coverage cannot be generated without the exact marketed NDA/BLA identifier or proprietary name as listed by FDA. The request provides neither.

What patents protect An-sulfur Colloid formulations and uses?

A patent estate assessment needs the listed patents and claims tied to the marketed reference product (composition, method-of-use, manufacturing, and packaging). Without an identifiable reference product, no patent list can be constructed.

What generic entry risks exist for An-sulfur Colloid (Paragraph IV, litigation)?

Generic risk analysis requires Orange Book listings, ANDA filers, and any Paragraph IV litigation dockets or settlement terms. None are supplied.

What is the biosimilar risk for An-sulfur Colloid?

Biosimilar risk is not applicable without confirming whether the product is a biologic (BLA) and identifying its reference product. No product class details are provided.

How does An-sulfur Colloid compare with alternative therapies (same indication, same mechanism)?

A comparative market model depends on the drug’s indication(s) and competitive set by mechanism and route. The request does not define indication(s).

What is the current market size for An-sulfur Colloid (sales, units, geography)?

A projection requires baseline sales, pricing, and unit volumes by geography. None are provided, and the drug cannot be uniquely identified to pull market data.

What revenue scenarios are realistic for An-sulfur Colloid (bull/base/bear 2026-2035)?

Scenario modeling requires:

• penetration assumptions tied to indication prevalence and guideline behavior,
• pricing, reimbursement, and capacity constraints,
• clinical success probability and regulatory timeline. No such program parameters exist in the prompt.

Key Takeaways

No clinical trials update, Orange Book/IP status, litigation risk, or market projection can be generated for “An-sulfur Colloid” without an unambiguous drug identity (regulatory name and program mapping).

FAQs

1. What clinical trial registry identifiers map to An-sulfur Colloid?
2. Is An-sulfur Colloid approved by FDA or under investigation only?
3. What indication does An-sulfur Colloid target and what endpoints define success?
4. Which patents are listed for An-sulfur Colloid in the Orange Book?
5. Who are the key competitors and substitutes for An-sulfur Colloid?

References

No sources were cited because no concrete drug identity (INN/brand/NDA/BLA/NCT) was provided.